How a Spanish innovator is bringing life-saving technology into the home.

In 2026, the medical world is celebrating a shift toward decentralized diagnostics, and at the forefront is Judit Giró Benet. The founder of The Blue Box has officially moved from “startup to scale-up” this year, as her urine-based breast cancer screening device enters major clinical trials across Europe and the UK.

The Technology of “The Blue Box”

Benet’s innovation is a masterclass in Vertical AI. By using an “Electronic Nose” to detect specific metabolites in urine associated with breast cancer, her device offers a non-invasive, radiation-free alternative to traditional mammography.

• The Entrepreneurial Vision: Benet identified a massive gap in the market—the “Fear Barrier.” Many women avoid screenings due to the discomfort of mammograms. By making the test as simple as a pregnancy test, she is solving a human problem with high-tech engineering.
• Global Recognition: In early 2026, Benet was named a semi-finalist for the European Prize for Women Innovators, signaling that the EU is ready to back “FemTech” as a primary pillar of its healthcare strategy.

The Business of HealthTech

For CEOs, Benet’s journey highlights the power of Purpose-Driven Innovation. She didn’t just build a better medical tool; she built a more accessible patient experience. In 2026, the most successful HealthTech founders are those who realize that the “User Interface” of healthcare is just as important as the clinical data.